Go Pro
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel Free INAB Stock Alerts

IN8bio (INAB) Financials

IN8bio logo
$1.24 -0.02 (-1.59%)
Closing price 04:00 PM Eastern
Extended Trading
$1.30 +0.06 (+4.84%)
As of 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for IN8bio

Annual Income Statements for IN8bio

This table shows IN8bio's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -17 0.00 -29 -30 -30 -19
Consolidated Net Income / (Loss)		 -19 -15 -29 -30 -30 -19
Net Income / (Loss) Continuing Operations		 -17 -15 -29 -30 -30 -19
Total Pre-Tax Income 		-17 -15 -29 -30 -30 -19
Total Operating Income		 -8.56 -15 -29 -30 -30 -19
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 17 15 29 30 31 20
Selling, General & Admin Expense		 3.18 7.31 14 14 13 9.65
Research & Development Expense		 5.38 7.35 14 17 17 10
Other Operating Expenses / (Income)		 8.56 - - -0.33 1.07 0.00
Total Other Income / (Expense), net		 0.00 0.00 0.00 0.00 0.23 0.42
Interest & Investment Income		 - - - 0.00 0.23 0.42
Basic Earnings per Share		 ($3.02) ($1.47) ($1.36) ($1.00) ($17.05) ($4.44)
Weighted Average Basic Shares Outstanding		 3.42M 9.97M 20.97M 29.86M 1.78M 4.37M
Diluted Earnings per Share		 ($3.02) ($1.47) ($1.36) ($1.00) ($17.05) ($4.44)
Weighted Average Diluted Shares Outstanding		 3.42M 9.97M 20.97M 29.86M 1.78M 4.37M

Quarterly Income Statements for IN8bio

This table shows IN8bio's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -7.17 -7.60 -8.56 -8.63 -7.09 -6.16 -5.55 -5.09 -3.85 -4.94 -5.09
Consolidated Net Income / (Loss)		 -7.17 -7.60 -8.56 -8.63 -7.09 -6.16 -5.55 -5.09 -3.85 -4.94 -5.09
Net Income / (Loss) Continuing Operations		 -7.17 -7.60 -8.48 -8.57 -7.06 -6.10 -5.55 -5.09 -3.85 -4.94 -5.09
Total Pre-Tax Income 		-7.17 -7.60 -8.48 -8.57 -7.06 -6.10 -5.55 -5.09 -3.85 -4.94 -5.09
Total Operating Income		 -7.17 -7.60 -8.56 -8.63 -7.09 -6.16 -5.55 -5.09 -3.85 -4.94 -5.09
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 7.17 7.60 8.65 8.69 7.11 6.22 5.66 5.20 3.97 5.03 5.27
Selling, General & Admin Expense		 3.38 3.08 3.74 3.53 2.73 2.63 2.69 2.71 1.86 2.39 2.65
Research & Development Expense		 3.79 4.52 4.90 5.16 3.31 3.59 2.97 2.49 2.10 2.65 2.61
Total Other Income / (Expense), net		 0.00 - 0.08 0.06 0.02 0.06 0.11 0.11 0.11 0.09 0.18
Interest & Investment Income		 0.00 - 0.08 0.06 0.02 0.06 0.11 0.11 0.11 0.09 0.18
Basic Earnings per Share		 ($0.23) ($0.20) ($0.20) ($5.51) ($4.49) ($3.45) ($2.16) ($1.24) ($0.85) ($1.13) ($0.26)
Weighted Average Basic Shares Outstanding		 31.55M 29.86M 43.29M 1.57M 1.58M 1.78M 2.58M 4.12M 4.54M 4.37M 19.47M
Diluted Earnings per Share		 ($0.23) ($0.20) ($0.20) ($5.51) ($4.49) ($3.45) ($2.16) ($1.24) ($0.85) ($1.13) ($0.26)
Weighted Average Diluted Shares Outstanding		 31.55M 29.86M 43.29M 1.57M 1.58M 1.78M 2.58M 4.12M 4.54M 4.37M 19.47M
Weighted Average Basic & Diluted Shares Outstanding		 31.99M 43.29M 44.12M 46.79M 72.48M 0.00 - 4.54M 4.63M 0.00 9.85M

Annual Cash Flow Statements for IN8bio

This table details how cash moves in and out of IN8bio's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 17 19 -19 3.10 -10 16
Net Cash From Operating Activities		 -7.13 -14 -24 -23 -24 -13
Net Cash From Continuing Operating Activities		 -7.13 -14 -24 -23 -24 -13
Net Income / (Loss) Continuing Operations		 -8.56 -15 -29 -30 -30 -19
Consolidated Net Income / (Loss)		 -8.56 -15 -29 -30 -30 -19
Depreciation Expense		 0.09 0.09 0.15 0.96 0.98 1.00
Amortization Expense		 0.00 0.70 0.96 1.54 1.68 1.50
Non-Cash Adjustments To Reconcile Net Income		 0.73 2.35 3.58 4.48 5.13 3.80
Changes in Operating Assets and Liabilities, net		 0.61 -2.00 -0.28 -0.32 -1.55 0.43
Net Cash From Investing Activities		 0.00 -0.31 -3.71 -0.60 -0.19 0.00
Net Cash From Continuing Investing Activities		 0.00 -0.31 -3.71 -0.60 -0.19 0.00
Purchase of Property, Plant & Equipment		 - 0.00 -3.69 -0.41 -0.10 0.00
Other Investing Activities, net		 0.00 -0.31 -0.02 -0.20 -0.08 0.00
Net Cash From Financing Activities		 25 33 8.99 27 14 29
Net Cash From Continuing Financing Activities		 25 33 8.99 27 14 29
Repurchase of Common Equity		 -1.34 -2.69 - 0.00 -0.09 0.00
Issuance of Common Equity		 0.50 36 9.54 28 15 27
Other Financing Activities, net		 0.01 -0.51 -0.55 -0.80 -0.77 1.57

Quarterly Cash Flow Statements for IN8bio

This table details how cash moves in and out of IN8bio's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -4.14 8.43 -8.27 -2.80 -6.22 7.13 0.77 1.34 -2.54 16 -5.15
Net Cash From Operating Activities		 -5.71 -4.85 -7.92 -6.09 -6.11 -4.03 -3.12 -3.93 -3.52 -2.14 -4.95
Net Cash From Continuing Operating Activities		 -5.71 -4.85 -7.92 -6.09 -6.16 -4.03 -3.12 -3.93 -3.52 -2.14 -4.95
Net Income / (Loss) Continuing Operations		 -7.17 -7.60 -8.56 -8.63 -7.09 -6.16 -5.55 -5.09 -3.85 -4.94 -5.09
Consolidated Net Income / (Loss)		 -7.17 -7.60 -8.56 -8.63 -7.09 -6.16 -5.55 -5.09 -3.85 -4.94 -5.09
Depreciation Expense		 0.24 0.24 0.24 0.23 0.25 0.25 0.26 0.26 0.24 0.25 0.25
Amortization Expense		 0.41 0.39 0.39 0.40 0.44 0.45 0.41 0.53 0.28 0.28 0.26
Non-Cash Adjustments To Reconcile Net Income		 1.27 1.29 1.28 1.20 1.80 0.86 1.00 1.02 0.89 0.90 0.61
Changes in Operating Assets and Liabilities, net		 -0.46 0.83 -1.27 0.70 -1.56 0.57 0.76 -0.63 -1.09 1.39 -0.96
Net Cash From Investing Activities		 -0.08 -0.07 -0.07 -0.08 - -0.03 0.00 - - - -0.01
Net Cash From Continuing Investing Activities		 -0.08 -0.07 -0.07 -0.08 - -0.03 0.00 - - - -0.01
Purchase of Property, Plant & Equipment		 - 0.00 -0.05 -0.02 - -0.03 0.00 - - - -0.01
Net Cash From Financing Activities		 1.65 13 -0.28 3.38 -0.11 11 3.89 5.27 0.99 18 -0.20
Net Cash From Continuing Financing Activities		 1.65 13 -0.28 3.38 -0.11 11 3.89 5.27 0.99 18 -0.20
Repurchase of Common Equity		 - - -0.09 - -0.09 0.09 0.00 - - - -0.09
Issuance of Common Equity		 1.89 14 0.00 3.53 -3.62 15 3.74 3.62 1.11 19 0.00
Other Financing Activities, net		 -0.24 -0.17 -0.19 -0.15 3.60 -4.04 0.16 1.65 -0.12 -0.11 -0.11

Annual Balance Sheets for IN8bio

This table presents IN8bio's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 21 42 33 34 21 32
Total Current Assets		 18 39 22 25 13 28
Cash & Equivalents		 18 37 18 21 11 27
Prepaid Expenses		 0.15 1.96 4.05 3.34 1.46 0.79
Plant, Property, & Equipment, net		 0.19 0.10 4.40 3.51 2.86 1.86
Total Noncurrent Assets		 2.44 3.15 6.41 5.57 5.51 2.54
Noncurrent Note & Lease Receivables		 0.00 0.70 1.69 1.36 1.07 0.30
Other Noncurrent Operating Assets		 2.44 2.44 4.72 4.21 4.44 2.25
Total Liabilities & Shareholders' Equity		 21 42 33 34 21 32
Total Liabilities		 2.59 4.04 10 8.77 6.47 4.72
Total Current Liabilities		 2.57 2.26 5.82 5.39 3.08 3.16
Accounts Payable		 0.62 0.40 2.09 0.92 0.39 0.31
Accrued Expenses		 1.78 1.24 2.34 2.96 1.05 1.63
Other Current Liabilities		 0.00 0.63 1.39 1.51 1.65 1.22
Total Noncurrent Liabilities		 0.02 1.78 4.49 3.38 3.38 1.56
Other Noncurrent Operating Liabilities		 0.00 1.78 4.49 3.38 3.38 1.56
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -17 38 23 25 14 28
Total Preferred & Common Equity		 -17 38 23 25 14 28
Preferred Stock		 - - 0.00 0.00 0.00 0.00
Total Common Equity		 -17 38 23 25 14 28
Common Stock		 1.46 71 84 116 136 169
Retained Earnings		 -18 -33 -61 -91 -122 -141

Quarterly Balance Sheets for IN8bio

This table presents IN8bio's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 26 0.00 22 16 20 19 17 26
Total Current Assets		 17 0.00 13 6.70 13 14 12 23
Cash & Equivalents		 13 13 10 4.00 12 13 11 22
Prepaid Expenses		 3.70 2.74 2.47 2.70 0.84 0.52 1.08 0.72
Plant, Property, & Equipment, net		 3.74 3.33 3.11 3.08 2.60 2.35 2.10 1.62
Total Noncurrent Assets		 5.92 0.26 6.70 6.18 4.54 3.28 2.90 1.98
Noncurrent Note & Lease Receivables		 1.58 0.00 1.53 1.30 0.83 0.54 0.42 0.19
Other Noncurrent Operating Assets		 4.34 0.26 5.17 4.70 3.71 2.74 2.48 1.79
Total Liabilities & Shareholders' Equity		 26 0.00 22 16 20 19 17 26
Total Liabilities		 8.45 0.00 8.88 7.38 5.99 4.13 3.58 3.48
Total Current Liabilities		 4.69 0.00 4.76 3.64 2.96 1.95 1.70 2.16
Accounts Payable		 0.75 0.00 1.44 1.14 0.58 0.38 0.20 0.45
Accrued Expenses		 2.44 0.90 1.53 0.77 1.15 0.64 0.42 0.68
Other Current Liabilities		 1.50 1.54 1.78 1.73 1.24 0.94 1.08 1.03
Total Noncurrent Liabilities		 3.76 4.18 4.12 3.74 3.04 2.18 1.88 1.33
Other Noncurrent Operating Liabilities		 3.76 4.18 4.12 3.74 3.04 2.18 1.88 1.33
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 18 0.00 14 8.59 14 15 13 23
Total Preferred & Common Equity		 18 18 14 8.59 14 15 13 23
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 18 0.00 14 8.59 14 15 13 23
Common Stock		 101 0.00 122 124 141 148 149 169
Retained Earnings		 -84 0.00 -108 -115 -127 -132 -136 -146

Annual Metrics And Ratios for IN8bio

This table displays calculated financial ratios and metrics derived from IN8bio's official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 18,754,553.00 24,502,157.00 31,991,130.00 72,483,253.00 4,634,396.00
DEI Adjusted Shares Outstanding		 0.00 625,152.00 816,739.00 1,066,371.00 2,416,108.00 4,634,396.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -34.92 -28.14 -12.60 -4.19
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -63.71% -97.75% -0.32% -1.00% 39.03%
EBIT Growth		 0.00% -71.24% -94.64% -5.21% -1.43% 36.13%
NOPAT Growth		 0.00% -71.24% -94.64% -5.21% -1.43% 36.13%
Net Income Growth		 0.00% 22.46% -94.64% -5.21% -1.43% 36.13%
EPS Growth		 0.00% 51.32% 7.48% 26.47% -1.43% 73.96%
Operating Cash Flow Growth		 0.00% -89.39% -78.56% 3.24% -3.47% 47.36%
Free Cash Flow Firm Growth		 0.00% 0.00% -111.16% 13.89% -4.47% 48.99%
Invested Capital Growth		 0.00% 222.78% 291.57% -19.67% -8.13% -86.12%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% -7.16% 1.70% 5.16% 5.77%
EBIT Q/Q Growth		 0.00% 0.00% -7.33% 0.66% 4.51% 5.90%
NOPAT Q/Q Growth		 0.00% 0.00% -7.33% 0.66% 4.51% 5.90%
Net Income Q/Q Growth		 0.00% 0.00% -21.35% 0.66% 4.51% 5.90%
EPS Q/Q Growth		 0.00% 0.00% -202.22% 9.91% 4.51% 2.42%
Operating Cash Flow Q/Q Growth		 0.00% -3.45% -31.46% 11.72% 3.29% 12.94%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 16.67% 3.69% 14.64%
Invested Capital Q/Q Growth		 0.00% 0.00% 137.35% -25.47% -23.79% -81.36%
Profitability Metrics		 - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 110.42% 100.00% 100.00% 100.00% 100.76% 100.00%
Interest Burden Percent		 200.00% 100.00% 100.00% 100.00% 99.24% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -103.14% -51.87% -93.64% -125.90% -154.44% -92.49%
Cash Return on Invested Capital (CROIC)		 0.00% -1,453.23% -817.67% -490.19% -599.14% -560.46%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 93.34% -19.83% -93.64% -125.90% -154.44% -92.49%
Return on Equity Simple (ROE_SIMPLE)		 113.98% -38.38% -125.47% -120.33% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -5.99 -10 -20 -21 -21 -14
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -71.86% -15.99% -31.00% -45.62% -56.36% -30.52%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -84.23% -147.16% -49.38%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -8.56 -15 -29 -30 -30 -19
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -8.47 -14 -27 -28 -28 -17
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 0.00 2.16 2.49 1.77 1.29 0.39
Price to Tangible Book Value (P/TBV)		 0.00 2.16 2.49 1.77 1.29 0.39
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 158.16 38.99 8.44 6.26 2.24 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 0.01 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.98 -0.97 -0.91 -0.83 -0.82 -0.91
Leverage Ratio		 1.14 1.12 1.24 1.40 1.39 1.27
Compound Leverage Factor		 2.28 1.12 1.24 1.40 1.38 1.27
Debt to Total Capital		 0.94% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.94% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 188.70% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -89.64% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 -0.02 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 2.12 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.03 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 3.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 7.61 11.04 -1.55 -3.02 -10.65 -5.81
Noncontrolling Interest Sharing Ratio		 190.49% 61.77% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - -
Current Ratio		 7.05 17.28 3.82 4.57 4.08 8.82
Quick Ratio		 7.00 16.41 3.12 3.95 3.61 8.57
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -11 -23 -20 -21 -11
Operating Cash Flow to CapEx		 0.00% 0.00% -653.86% -5,762.96% -23,220.19% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - -
Invested Capital		 0.36 1.16 4.55 3.66 3.36 0.47
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 0.80 3.39 -0.90 -0.30 -2.89
Enterprise Value (EV)		 57 45 38 23 7.52 -16
Market Capitalization		 40 82 57 44 19 11
Book Value per Share		 ($4.85) $2.04 $0.93 $0.78 $0.20 $5.95
Tangible Book Value per Share		 ($4.85) $2.04 $0.93 $0.78 $0.20 $5.95
Total Capital		 18 38 23 25 14 28
Total Debt		 0.17 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -18 -37 -18 -21 -11 -27
Capital Expenditures (CapEx)		 0.00 0.00 3.69 0.41 0.10 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -2.39 -0.30 -1.77 -2.05 -1.63 -2.37
Debt-free Net Working Capital (DFNWC)		 16 37 16 19 9.50 25
Net Working Capital (NWC)		 16 37 16 19 9.50 25
Net Nonoperating Expense (NNE)		 13 4.40 8.56 9.00 9.13 5.83
Net Nonoperating Obligations (NNO)		 -18 -37 -18 -21 -11 -27
Total Depreciation and Amortization (D&A)		 0.09 0.79 1.10 2.50 2.66 2.50
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($1.47) ($1.36) ($1.00) ($17.10) ($4.44)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 18.81M 20.97M 29.86M 1.78M 4.37M
Adjusted Diluted Earnings per Share		 $0.00 ($1.47) ($1.36) ($1.00) ($17.10) ($4.44)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 18.81M 20.97M 29.86M 1.78M 4.37M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($1.47) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 9.97M 24.94M 43.29M 0.00 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -5.99 -10 -20 -21 -21 -14
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -7.11% -18.38% 0.00% 0.00% -0.29% 0.00%

Quarterly Metrics And Ratios for IN8bio

This table displays calculated financial ratios and metrics derived from IN8bio's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 31,601,145.00 31,991,130.00 43,287,325.00 44,123,949.00 46,786,948.00 72,483,253.00 72,483,253.00 72,483,253.00 4,539,717.00 4,634,396.00 4,634,396.00
DEI Adjusted Shares Outstanding		 1,053,371.00 1,066,371.00 1,442,911.00 1,470,798.00 1,559,565.00 2,416,108.00 2,416,108.00 2,416,108.00 4,539,717.00 4,634,396.00 4,634,396.00
DEI Earnings Per Adjusted Shares Outstanding		 -6.81 -7.13 -5.93 -5.87 -4.54 -2.55 -2.30 -2.11 -0.85 -1.07 -1.10
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 8.82% 6.39% -14.35% -13.00% 1.93% 21.70% 38.45% 46.11% 47.98% 19.00% 5.96%
EBIT Growth		 3.11% 2.56% -13.78% -11.85% 1.16% 18.93% 35.18% 40.97% 45.61% 19.77% 8.29%
NOPAT Growth		 3.11% 2.56% -13.78% -11.85% 1.16% 18.93% 35.18% 40.97% 45.61% 19.77% 8.29%
Net Income Growth		 3.11% 2.56% -13.78% -11.85% 1.16% 18.93% 35.18% 40.97% 45.61% 19.77% 8.29%
EPS Growth		 32.35% 35.48% 33.33% -11.85% 1.16% 18.93% 35.18% 77.50% 81.07% 67.25% 87.96%
Operating Cash Flow Growth		 0.49% 38.99% -6.45% -14.11% -6.97% 16.95% 60.58% 35.53% 42.33% 46.90% -58.46%
Free Cash Flow Firm Growth		 -69.13% 50.00% 102.08% 49.06% 44.26% 9.24% -2,856.26% 54.03% 82.26% 85.87% 60.83%
Invested Capital Growth		 155.82% -19.67% -104.88% -27.77% -10.16% -8.13% 788.24% -40.86% -43.26% -86.12% -57.77%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 7.86% -6.88% -13.76% -0.86% 20.03% 14.67% 10.57% 11.70% 22.81% -32.88% -3.82%
EBIT Q/Q Growth		 7.08% -5.98% -12.69% -0.78% 17.88% 13.07% 9.90% 8.22% 24.34% -28.23% -2.99%
NOPAT Q/Q Growth		 7.08% -5.98% -12.69% -0.78% 17.88% 13.07% 9.90% 8.22% 24.34% -28.23% -2.99%
Net Income Q/Q Growth		 7.08% -5.98% -12.69% -0.78% 17.88% 13.07% 9.90% 8.22% 24.34% -28.23% -2.99%
EPS Q/Q Growth		 14.81% 13.04% 0.00% -0.78% 17.88% 13.07% 9.90% -1,671.43% 31.45% -32.94% 76.99%
Operating Cash Flow Q/Q Growth		 -7.03% 15.11% -63.28% 23.08% -0.33% 34.09% 22.49% -25.78% 10.26% 39.30% -131.28%
Free Cash Flow Firm Q/Q Growth		 13.81% 44.74% 105.05% -2,215.97% 5.69% 10.02% -53.50% 64.71% 63.59% 28.34% -325.45%
Invested Capital Q/Q Growth		 4.05% -25.47% -107.91% 1,277.85% 29.44% -23.79% -40.77% 1.21% 24.19% -81.36% 80.26%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.98% 100.70% 100.33% 101.05% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.00% 100.00% 99.03% 99.30% 99.68% 98.96% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -127.67% -125.90% -369.84% -180.45% -241.97% -154.44% -395.26% -165.56% -189.72% -92.49% -103.55%
Cash Return on Invested Capital (CROIC)		 -707.58% -490.19% 0.00% -518.95% -468.63% -599.14% -1,079.71% -566.07% -363.59% -560.46% -858.04%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -127.67% -125.90% -369.84% -180.45% -241.97% -154.44% -395.26% -165.56% -189.72% -92.49% -103.55%
Return on Equity Simple (ROE_SIMPLE)		 -170.10% 0.00% -177.13% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -5.02 -5.32 -5.99 -6.04 -4.96 -4.31 -3.89 -3.57 -2.70 -3.46 -3.56
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -10.62% -11.55% -46.08% -18.96% -24.96% -11.41% -27.35% -13.04% -15.55% -7.76% -9.03%
Return On Investment Capital (ROIC_SIMPLE)		 - -21.33% 0.00% -44.35% -57.76% -29.78% -28.00% -23.40% -20.45% -12.55% -15.64%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -7.17 -7.60 -8.56 -8.63 -7.09 -6.16 -5.55 -5.09 -3.85 -4.94 -5.09
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -6.52 -6.97 -7.93 -8.00 -6.40 -5.46 -4.88 -4.31 -3.33 -4.42 -4.59
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.85 1.77 0.00 2.74 1.47 1.29 0.87 0.00 0.75 0.39 0.30
Price to Tangible Book Value (P/TBV)		 1.85 1.77 0.00 2.74 1.47 1.29 0.87 0.00 0.75 0.39 0.30
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 4.08 6.26 0.00 7.97 1.96 2.24 0.07 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.86 -0.83 -0.66 -0.77 -0.65 -0.82 -0.88 -0.81 -0.68 -0.91 -0.92
Leverage Ratio		 1.36 1.40 1.47 1.47 1.60 1.39 1.43 1.45 1.50 1.27 1.26
Compound Leverage Factor		 1.36 1.40 1.46 1.46 1.60 1.37 1.43 1.45 1.50 1.27 1.26
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -2.49 -0.83 0.00 -5.06 -10.33 -6.83 -8.09 0.00 -9.75 -4.33 -6.31
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.53 4.57 0.00 2.66 1.84 4.08 4.30 7.03 6.91 8.82 10.50
Quick Ratio		 2.74 3.95 0.00 2.15 1.10 3.61 4.02 6.77 6.28 8.57 10.17
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -8.01 -4.42 0.22 -4.73 -4.46 -4.02 -6.16 -2.17 -0.79 -0.57 -2.41
Operating Cash Flow to CapEx		 0.00% 0.00% -15,838.00% -29,004.76% 0.00% -12,206.06% 0.00% 0.00% 0.00% 0.00% -54,966.67%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 4.90 3.66 -0.29 3.40 4.41 3.36 1.99 2.01 2.50 0.47 0.84
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 2.99 -0.90 -6.22 -1.31 -0.50 -0.30 2.28 -1.39 -1.91 -2.89 -1.15
Enterprise Value (EV)		 20 23 38 27 8.63 7.52 0.14 0.00 -0.84 -16 -15
Market Capitalization		 33 44 51 37 13 19 12 0.00 9.85 11 6.86
Book Value per Share		 $0.56 $0.78 $0.00 $0.31 $0.18 $0.20 $5.39 $3.70 $2.91 $5.95 $1.17
Tangible Book Value per Share		 $0.56 $0.78 $0.00 $0.31 $0.18 $0.20 $5.39 $3.70 $2.91 $5.95 $1.17
Total Capital		 18 25 0.00 14 8.59 14 14 15 13 28 23
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -13 -21 -13 -10 -4.00 -11 -12 -13 -11 -27 -22
Capital Expenditures (CapEx)		 0.00 -0.00 0.05 0.02 0.00 0.03 0.00 0.00 0.00 0.00 0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.99 -2.05 -13 -2.29 -0.93 -1.63 -2.12 -1.44 -0.62 -2.37 -1.44
Debt-free Net Working Capital (DFNWC)		 12 19 0.00 7.92 3.07 9.50 9.77 12 10 25 21
Net Working Capital (NWC)		 12 19 0.00 7.92 3.07 9.50 9.77 12 10 25 21
Net Nonoperating Expense (NNE)		 2.15 2.28 2.57 2.59 2.13 1.85 1.67 1.53 1.16 1.48 1.53
Net Nonoperating Obligations (NNO)		 -13 -21 -0.29 -10 -4.18 -11 -12 -13 -11 -27 -22
Total Depreciation and Amortization (D&A)		 0.65 0.63 0.63 0.63 0.69 0.70 0.67 0.78 0.53 0.52 0.50
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.23) ($0.20) ($0.20) ($5.70) ($4.50) ($103.50) ($2.10) ($1.24) ($0.85) ($1.13) ($0.26)
Adjusted Weighted Average Basic Shares Outstanding		 31.55M 29.86M 43.29M 1.50M 1.58M 59.50K 2.78M 4.12M 4.54M 4.37M 19.47M
Adjusted Diluted Earnings per Share		 ($0.23) ($0.20) ($0.20) ($5.70) ($4.50) ($103.50) ($2.10) ($1.24) ($0.85) ($1.13) ($0.26)
Adjusted Weighted Average Diluted Shares Outstanding		 31.55M 29.86M 43.29M 1.50M 1.58M 59.50K 2.78M 4.12M 4.54M 4.37M 19.47M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 ($103.50) $0.00 $0.00 $0.00 ($1.13) $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 31.99M 43.29M 44.12M 1.56M 2.42M 0.00 0.00 4.54M 4.63M 0.00 9.85M
Normalized Net Operating Profit after Tax (NOPAT)		 -5.02 -5.32 -5.99 -6.04 -4.96 -4.31 -3.89 -3.57 -2.70 -3.46 -3.56
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% -0.29% -0.28% -0.57% -0.29% 0.00% 0.00% 0.45% 0.00% -0.46%

Financials Breakdown Chart

Key Financial Trends

IN8bio (NASDAQ: INAB) remains a pre-revenue biotech with no product sales, persistent operating losses, and significant reliance on equity financing. The latest quarter shows a larger cash balance than the prior quarter, but that improvement was driven by financing, not operations. Over the last four years, the company has consistently burned cash, and recent share issuance has helped fund operations while also diluting shareholders.

  • Cash & equivalents rose to $21.9 million in Q1 2026 from $10.7 million in Q3 2025, giving the company more short-term liquidity.
  • The company posted net financing inflows in several periods, showing it has been able to access capital markets to stay funded.
  • Operating expenses in Q1 2026 were $5.3 million, slightly below the $5.0 million to $7.1 million range seen in recent quarters, suggesting some expense control versus the peak periods in 2024.
  • IN8bio continues to hold a meaningful asset base, with $26.3 million in total assets at the end of Q1 2026, including cash, PPE, and other operating assets.
  • The company still generated zero revenue in every quarter provided, so the current story remains entirely clinical/development driven.
  • Research and development spending remains elevated at $2.6 million in Q1 2026, consistent with a company still investing in pipeline development.
  • Non-cash charges such as depreciation and amortization help reduce reported cash burn somewhat, but they do not offset the underlying operating losses.
  • Q1 2026 net loss was $5.1 million, with operating cash outflow of $4.9 million, indicating the business is still consuming cash at a meaningful rate.
  • Share count has expanded dramatically over time. Basic weighted average shares were 19.5 million in Q1 2026 versus just 2.6 million in Q1 2025, a sign of heavy dilution.
  • Retained earnings remain deeply negative at $(146.2) million, reflecting years of accumulated losses.

Trend summary: IN8bio has not yet shown revenue traction, profitability, or positive operating cash flow. The balance sheet is currently stronger than it was a few quarters ago because of equity raises, but that comes with dilution risk. For retail investors, the main question is whether the company can advance its pipeline enough to justify continued financing and eventual commercialization before cash burn becomes a bigger problem.

07/22/26 12:48 AM ETAI Generated. May Contain Errors.

IN8bio Financials - Frequently Asked Questions

According to the most recent income statement we have on file, IN8bio's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

IN8bio's net income appears to be on an upward trend, with a most recent value of -$19.44 million in 2025, rising from -$18.90 million in 2020. The previous period was -$30.44 million in 2024. Check out IN8bio's forecast to explore projected trends and price targets.

IN8bio's total operating income in 2025 was -$19.44 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $19.86 million

Over the last 5 years, IN8bio's total revenue changed from $0.00 in 2020 to $0.00 in 2025, a change of 0.0%.

IN8bio's total liabilities were at $4.72 million at the end of 2025, a 26.9% decrease from 2024, and a 82.5% increase since 2020.

In the past 5 years, IN8bio's cash and equivalents has ranged from $11.12 million in 2024 to $37.02 million in 2021, and is currently $27.09 million as of their latest financial filing in 2025.

Over the last 5 years, IN8bio's book value per share changed from -4.85 in 2020 to 5.95 in 2025, a change of -222.6%.


Related Companies

Financial statements for NASDAQ:INAB last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Elon’s new "tollbooth"
The SpaceX IPO was valued at $1.75 trillion. But one analyst says fighting over those shares may be the wrong ...
Weiss Ratings | Sponsoredtc pixel
Oil is settling in yuan now - here's what that means for gold
Saudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every...
Golden Portfolio | Sponsoredtc pixel